A cholesterol hitchhiker makes gene-silencing drugs up to 16 times stronger in the brain

Getting medicines into the brain and spinal cord is one of medicine's hardest delivery problems. A team led by Mitsugu Yanagidaira, Tetsuya Nagata and Takanori Yokota at the Institute of Science Tokyo built a cholesterol-linked platform, Chol-HDO[PMO], that hitches a ride on lipoproteins — the particles that ferry fats — in cerebrospinal fluid. In mouse tests, reported in Nature Communications, it delivered up to a 16-fold increase in gene-targeting potency over conventional antisense drugs, with long-lasting effects and no noticeable acute nerve toxicity or immune reactions. It is early, animal-stage work — a foundation, not a cure.